| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| prazosin hydrochloride | Tablet, uncoated | 5.476 mg | Resolved | Available | Unexpected increase in consumer demand | 2/08/2024 |
| fluorouracil | Cream | 50 mg/g | Current | Limited Availability | Manufacturing | 2/08/2024 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 2/08/2024 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 2/08/2024 |
| emtricitabine~tenofovir disoproxil fumarate | Tablet, film coated | 200 mg~300 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 2/08/2024 |
| dasatinib | Tablet, film coated | 100 mg | Anticipated | Available | Manufacturing | 2/08/2024 |
| atomoxetine hydrochloride | Capsule, hard | 45.5 mg | Current | Limited Availability | Manufacturing | 2/08/2024 |
| risperidone | Oral Liquid, solution | 1 mg/mL | Current | Unavailable | Manufacturing | 2/08/2024 |
| olmesartan medoxomil~hydrochlorothiazide~amlodipine besilate | Tablet, film coated | 40 mg~25 mg~6.95 mg | Current | Unavailable | Manufacturing | 2/08/2024 |
| mycophenolate sodium | Tablet, enteric coated | 384.7 mg | Anticipated | Available | Manufacturing | 2/08/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 2/08/2024 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~13.88 mg | Current | Limited Availability | Manufacturing | 2/08/2024 |
| erythromycin ethyl succinate | Oral Liquid, powder for | 468 mg | Anticipated | Available | Unexpected increase in consumer demand | 2/08/2024 |
| heparin sodium | Injection, solution | 10 IU/mL | Anticipated | Available | Manufacturing | 2/08/2024 |
| sodium lactate~icodextrin~magnesium chloride hexahydrate~calcium chloride dihydrate~sodium chloride | Solution, dialysis | 4.5 g/L~75 g/L~51 mg/L~257 mg/L~5.4 g/L | Current | Limited Availability | Manufacturing | 2/08/2024 |
| medroxyprogesterone acetate | Injection, suspension | 150 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 1/08/2024 |
| gliclazide | Tablet, modified release | 30 mg | Current | Unavailable | Manufacturing | 1/08/2024 |
| levetiracetam | Tablet, film coated | 250 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 1/08/2024 |
| enalapril maleate | Tablet | 10 mg | Current | Unavailable | Manufacturing | 1/08/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Unavailable | Manufacturing | 1/08/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 1/08/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 1/08/2024 |
| tranexamic acid | Injection, solution | 1000 mg | Anticipated | Available | Commercial Changes / Commercial viability | 1/08/2024 |
| chromium(51Cr) edetate | Injection, solution | 8 MBq/mL | Current | Unavailable | Manufacturing | 1/08/2024 |
| desvenlafaxine benzoate | Tablet, modified release | 73.16 mg | Resolved | Available | Manufacturing | 1/08/2024 |
| cefepime hydrochloride monohydrate | Injection, powder for | 2378.5 mg | Current | Limited Availability | Manufacturing | 1/08/2024 |
| ribavirin | Tablet, film coated | 200 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 1/08/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 1/08/2024 |
| imatinib mesilate | Capsule, hard | 119.47 mg | Anticipated | Available | Manufacturing | 1/08/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Anticipated | Available | Manufacturing | 1/08/2024 |
| gliclazide | Tablet, modified release | 30 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 1/08/2024 |
| cinacalcet hydrochloride | Tablet, film coated | 66 mg | Current | Unavailable | Manufacturing | 1/08/2024 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~82.725 mg | Current | Unavailable | Manufacturing | 1/08/2024 |
| modafinil | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 1/08/2024 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Current | Unavailable | Manufacturing | 1/08/2024 |
| lurasidone hydrochloride | Tablet, film coated | 40 mg | Current | Unavailable | Manufacturing | 1/08/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.8 mg | Current | Limited Availability | Manufacturing | 1/08/2024 |
| larotrectinib sulfate | Oral Liquid, solution | 24.6 mg/mL | Resolved | Available | Manufacturing | 1/08/2024 |
| heparin sodium | Injection, solution | 1000 IU/mL | Current | Unavailable | Manufacturing | 1/08/2024 |
| doxycycline monohydrate | Tablet, uncoated | 104.1 mg | Current | Limited Availability | Manufacturing | 1/08/2024 |
| sodium pertechnetate(99mTc) | Injection, solution | 20 GBq | Current | Limited Availability | Manufacturing | 1/08/2024 |
| sodium pertechnetate(99mTc) | Injection | 370 GBq | Current | Limited Availability | Manufacturing | 1/08/2024 |
| baclofen | Tablet, uncoated | 10 mg | Resolved | Available | Manufacturing | 1/08/2024 |
| ethosuximide | Capsule, soft | 250 mg | Current | Unavailable | Manufacturing | 1/08/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Anticipated | Available | Manufacturing | 31/07/2024 |
| griseofulvin | Tablet, uncoated | 125 mg | Current | Unavailable | Manufacturing | 31/07/2024 |
| olanzapine | Tablet, uncoated | 7.5 mg | Resolved | Available | Manufacturing | 31/07/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~5.198 mg | Current | Limited Availability | Manufacturing | 31/07/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.791 mg | Resolved | Available | Manufacturing | 31/07/2024 |
| entecavir | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 31/07/2024 |
| oxycodone hydrochloride | Capsule, hard | 10 mg | Current | Unavailable | Commercial Changes / Commercial viability | 31/07/2024 |
| rosuvastatin calcium | Tablet, film coated | 5.21 mg | Current | Limited Availability | Manufacturing | 31/07/2024 |
| emtricitabine~tenofovir disoproxil maleate | Tablet, film coated | 200 mg~300 mg | Current | Limited Availability | Manufacturing | 31/07/2024 |
| mercaptopurine monohydrate | Tablet | 50 mg | Current | Limited Availability | Manufacturing | 31/07/2024 |
| ketorolac trometamol | Injection, solution | 30 mg/mL | Current | Unavailable | Manufacturing | 31/07/2024 |
| Avalglucosidase alfa | Injection, powder for | 100 mg | Resolved | Available | Manufacturing | 31/07/2024 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 31/07/2024 |
| ezetimibe~rosuvastatin calcium | Tablet | 10 mg~10.4 mg | Current | Limited Availability | Manufacturing | 31/07/2024 |
| rifampicin | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 31/07/2024 |
| clarithromycin | Oral Liquid, powder for | 50 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 31/07/2024 |
| varenicline tartrate~varenicline tartrate | Tablet, film coated | .85 mg~1.71 mg | Current | Unavailable | Manufacturing | 30/07/2024 |
| varenicline tartrate | Tablet, film coated | 1.71 mg | Current | Unavailable | Manufacturing | 30/07/2024 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Manufacturing | 30/07/2024 |
| albendazole | Tablet, chewable | 400 mg | Resolved | Available | Commercial Changes / Commercial viability | 30/07/2024 |
| salbutamol sulfate | Inhalation, conventional | 3 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| sodium pertechnetate(99mTc) | Injection, solution | 18.5 GBq | Current | Unavailable | Manufacturing | 29/07/2024 |
| paliperidone | Tablet, modified release | 6 mg | Resolved | Available | Manufacturing | 29/07/2024 |
| Somatropin | Injection, powder for | 12 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 29/07/2024 |
| donepezil hydrochloride | Tablet, film coated | 5 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 29/07/2024 |
| omeprazole | Capsule | 20 mg | Current | Limited Availability | Manufacturing | 29/07/2024 |
| drospirenone~ethinylestradiol | Tablet | 3 mg~30 microgram | Resolved | Available | Manufacturing | 29/07/2024 |
| trandolapril | Capsule, hard | .5 mg | Current | Limited Availability | Manufacturing | 29/07/2024 |
| trandolapril | Capsule, hard | 1 mg | Anticipated | Available | Manufacturing | 29/07/2024 |
| Omalizumab | Injection, solution | 150 mg | Current | Emergency Supply Only | Manufacturing | 29/07/2024 |
| quetiapine fumarate | Tablet, film coated | 345.36 mg | Anticipated | Available | Manufacturing | 29/07/2024 |
| adefovir dipivoxil | Tablet | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 29/07/2024 |
| temozolomide | Capsule, hard | 180 mg | Anticipated | Available | Manufacturing | 29/07/2024 |
| rosuvastatin calcium | Tablet, film coated | 41.68 mg | Current | Unavailable | Commercial Changes / Commercial viability | 29/07/2024 |
| potassium clavulanate~amoxicillin trihydrate | Tablet, film coated | 148.875 mg~1006.25 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| mesalazine | Tablet, enteric coated | 800 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 29/07/2024 |
| tadalafil | Tablet | 5 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 29/07/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| cisplatin | Injection, concentrated | 1 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 29/07/2024 |
| cisplatin | Injection, concentrated | 1 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 29/07/2024 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~41.363 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 41.363 mg~10 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| dimethyl fumarate | Capsule, enteric | 240 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 29/07/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 29/07/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| mesalazine | Tablet, enteric coated | 1.6 g | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 29/07/2024 |
| lacosamide | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| mycophenolate mofetil | Suspension | 200 mg/mL | Current | Limited Availability | Manufacturing | 29/07/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 109 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 54.5 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 27.25 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.6 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| norethisterone acetate~estradiol | Drug delivery system, transdermal | 2.7 mg~.62 mg | Current | Unavailable | Manufacturing | 29/07/2024 |
| baclofen | Tablet | 10 mg | Resolved | Available | Manufacturing | 29/07/2024 |
2024年8月6日